BioSpace News Archive

Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2018.

GAAP EPS from Continuing Operations of $0.76; Adj. EPS Increases 41% to $1.37

edivir AB announced that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC).

Trial to Assess Efficacy and Safety of Investigational Drug MNK-1411 in Patients with DMD

Revenues of $43.1 Billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year

Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.

BioTime, Inc. reported that Gordon H. Sasaki, M.D., F.A.C.S., has initiated his independent investigator-initiated study of Premvia™ combined with the patient’s own fat for volume augmentation of the hand.

Reports Revenue of $1.4 Billion, Growing 12%, and Net Income of $384 Million

Reports $1.9 million of Adjusted EBITDA on $5.9 million of Revenue

BioLife Solutions, Inc. announced that the Company’s second quarter 2018 financial results will be released before market open on Thursday, August 9, 2018, and that the Company will host a conference call and live webcast at 10:00 a.m. ET (7:00 a.m. PT) that morning. Management will provide an overview of the Company’s financial results and a general business update.